ArticleNature medicine2026

Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

Miao Yu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.